新股消息 | 德适生物再度递表港交所 专注于开发医学影像产品及服务的医疗器械

Company Overview - Deshi Biotechnology Co., Ltd. focuses on developing medical imaging products and services, with a diverse product portfolio aimed at enhancing diagnostic efficiency and service quality [3][4] - The core product, AI AutoVision, is designed for chromosome karyotype analysis, supporting prenatal diagnosis of birth defects and assisted reproductive diagnosis [3][4] Product Pipeline - The company has developed six medical imaging software products, three commercialized medical devices, and four main reagents and consumables [3][5] - AI AutoVision has achieved 100% sensitivity and specificity in detecting numerical abnormalities and 94.05% sensitivity with 100% specificity for structural abnormalities [3][5] Financial Performance - For the fiscal year 2023, the company reported revenues of approximately RMB 52.84 million, with a gross profit of RMB 37.50 million [8][10] - The company recorded a net loss of RMB 56.12 million for the same period [9] Market Overview - The global smart medical imaging detection market is projected to grow from USD 400 million in 2019 to USD 1.6 billion by 2024, with a compound annual growth rate (CAGR) of 34.6% [11] - In China, the market is expected to expand from RMB 100 million in 2019 to RMB 2.4 billion by 2024, with a CAGR of 80.3% [14] Shareholding Structure - As of the latest available date, the major shareholders include Dr. Song, who holds approximately 30.04% of the shares, and several investment platforms managed by him, collectively controlling about 52.06% of the voting rights [19][21]